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Background: Diabetes increases adverse outcomes following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG); 
however, the impact of metabolic syndrome is unclear. This study examines the effects of diabetes and metabolic syndrome on 3-year outcomes 
following PCI and CABG to determine the optimal revascularization option for patients with these conditions.
Methods: Patients (N=1800) with left main and/or 3-vessel coronary artery stenoses were randomized to receive either PCI with TAXUS Express 
paclitaxel-eluting stents (PES) or CABG. Outcomes in subgroups with (N=452) or without (N=1348) diabetes and with (N=656) or without (N=777) 
metabolic syndrome were examined.
Results: Compared to CABG, PES treatment resulted in significantly higher 3-year major adverse cardiac and cerebrovascular event (MACCE) and 
revascularization rates in both diabetic and non-diabetic patients. In diabetic patients, three-year MACCE rates were 22.9% (CABG) and 37.0% 
(PES, P=0.002). Cardiac death rates were 4.8% (CABG) and 8.8% (PES, P=0.11) in diabetic patients. Both diabetes and lesion complexity increased 
adverse event risk in the PES arm, but appeared to have little impact on clinical outcomes after CABG. Compared to CABG, PES treatment yielded 
comparable MACCE in both diabetic (30.5% vs. 29.8%, P=0.98) and non-diabetic (20.2% vs. 20.3%, P=0.99) patients with low lesion complexity 
(SYNTAX scores ≤22); however, in patients with SYNTAX scores ≥33, events rates were lower in CABG compared to PES in both diabetic (18.5% vs. 
45.9%, P<0.001) and non-diabetic (19.8% vs. 30.0%, P=0.01) patients. Metabolic syndrome alone, in the absence of diabetes, had little impact on 
outcomes. In patients with metabolic syndrome only, the 3-year MACCE rates were 18.5% (CABG) and 24.9% (PES, P=0.10).
Conclusions: These exploratory analyses suggest that in patients with complex left main and/or 3-vessel disease, 3-year MACCE is higher with 
PES treatment compared to CABG. While PES is a potential treatment option in diabetic patients with less complex lesions, CABG should be used for 
patients with more complex anatomical disease, especially those with concurrent diabetes.
